Chinese CROs to Adopt OmniComm TrialOne Solution
OmniComm Systems announces the signing of contracts to provide the company’s TrialOne clinical automation solution to three clinical research organizations in China.
OmniComm Systems announces the signing of contracts to provide the company’s TrialOne clinical automation solution to three clinical research organizations in China. The agreements for TrialOne were made with Xiyuan Hospital, the Chinese Anti-Cancer Association (CACA) and eStart Medical Technology Co., Ltd.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
How the NIMBLE Study Supported Adherence With Quarterly Dosing of CemdisiranSeptember 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
